Patents by Inventor Guo-Liang Yu
Guo-Liang Yu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6861226Abstract: The invention relates to hESF I, II and III polypeptides, polynucleotides encoding the polypeptides, methods for producing the polypeptides, in particular by expressing the polynucleotides, and agonists and antagonists of the polypeptides. The invention further relates to methods for utilizing such polynucleotides, polypeptides, agonists and antagonists for applications, which relate, in part, to research, diagnostic and clinical arts.Type: GrantFiled: November 6, 2001Date of Patent: March 1, 2005Assignee: Human Genome Sciences, Inc.Inventors: Jian Ni, Guo-Liang Yu, Reiner L. Gentz
-
Publication number: 20050026179Abstract: The invention relates to hESF I, II and III polypeptides, polynucleotides encoding the polypeptides, methods for producing the polypeptides, in particular by expressing the polynucleotides, and agonists and antagonists of the polypeptides. The invention further relates to methods for utilizing such polynucleotides, polypeptides, agonists and antagonists for applications, which relate, in part, to research, diagnostic and clinical arts.Type: ApplicationFiled: April 8, 2004Publication date: February 3, 2005Applicant: Human Genome Sciences, Inc.Inventors: Jian Ni, Guo-Liang Yu, Reiner Gentz
-
Publication number: 20050026254Abstract: The present invention relates to huXAG-1, huXAG-2 and huXAG-3 proteins which are novel human growth factors. In particular, isolated nucleic acid molecules are provided encoding the huXAG-1, huXAG-2 and huXAG-3 proteins. huXAG-1, huXAG-2 and huXAG-3 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of huXAG-1, huXAG-2 or huXAG-3 activity. Also provided are diagnostic and therapeutic uses of huXAG-1. huXAG-2 and huXAG-3.Type: ApplicationFiled: August 20, 2004Publication date: February 3, 2005Applicant: Human Genome Sciences, Inc.Inventors: Guo-Liang Yu, Patrick Dillon, Reinhard Ebner, Gregory Endress
-
Patent number: 6831152Abstract: Human colon specific gene polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polynucleotides or polypeptides as a diagnostic marker for colon cancer and as an agent to determine if colon cancer has metastasized. Also disclosed are antibodies specific to the colon specific gene polypeptides which may be used to target cancer cells and be used as part of a colon cancer vaccine. Methods of screening for agonists and antagonists for the polypeptide and therapeutic uses of the antagonists are disclosed.Type: GrantFiled: November 19, 2001Date of Patent: December 14, 2004Assignee: Human Genome Sciences, Inc.Inventors: Guo-Liang Yu, Craig Rosen
-
Patent number: 6824767Abstract: Human TNF-gamma-alpha and TNF-gamma-beta polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptides to inhibit cellular growth, for example in a tumor or cancer, for facilitating wound-healing, to provide resistance against infection, induce inflammatory activities, and stimulating the growth of certain cell types to treat diseases, for example restenosis. Also disclosed are diagnostic methods for detecting a mutation in the TNF-gamma-alpha and TNF-gamma-beta nucleic acid sequences or overexperession of the TNF-gamma-alpha and TNF-gamma-beta polypeptides. Antagonists against such polypeptides and their use as a therapeutic to treat cachexia, septic shock, cerebral malaria, inflammation, arthritis and graft-rejection are also disclosed.Type: GrantFiled: February 8, 1999Date of Patent: November 30, 2004Assignee: Human Genome Sciences, Inc.Inventors: Guo-Liang Yu, Jian Ni, Craig A. Rosen, Jun Zhang
-
Patent number: 6818412Abstract: The present invention relates to huXAG-1, huXAG-2 and huXAG-3 proteins which are novel human growth factors. In particular, isolated nucleic acid molecules are provided encoding the huXAG-1, huXAG-2 and huXAG-3 proteins. huXAG-1, huXAG-2 and huXAG-3 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of huXAG-1, huXAG-2 or huXAG-3 activity. Also provided are diagnostic and therapeutic uses of huXAG-1. huXAG-2 and huXAG-3.Type: GrantFiled: February 21, 2002Date of Patent: November 16, 2004Assignee: Human Genome Sciences, Inc.Inventors: Guo-Liang Yu, Patrick J. Dillon, Reinhard Ebner, Gregory A. Endress
-
Patent number: 6812327Abstract: The present invention relates to a novel Neutrokine-alpha, and a splice variant thereof designated Neutrokine-alphaSV, polynucleotides and polypeptides which are members of the TNF family. In particular isolated nucleic acid molecules are provided encoding the human Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokine-alpha and/or Neutrokine-alphaSV agonists and antagonists of Neutrokine-alpha and/or Neutrokine-alphaSV activity. Also producing the same. The invention further relates to screening methods for identifying agonists and antagonists of Neutrokine-alpha and/or Neutrokine-alphaSV activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.Type: GrantFiled: February 22, 2000Date of Patent: November 2, 2004Assignee: Human Genome Sciences, Inc.Inventors: Guo-Liang Yu, Reinhard Ebner, Jian Ni, Craig A. Rosen
-
Patent number: 6806351Abstract: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.Type: GrantFiled: February 1, 2001Date of Patent: October 19, 2004Assignee: Human Genome Sciences, Inc.Inventors: Steven M. Ruben, Daniel R. Soppet, Reinhard Ebner, Henrik S. Olsen, Paul E. Young, John M. Greene, Ann M. Ferrie, Guo-Liang Yu, Jian Ni, Craig A. Rosen, Laurie A. Brewer, Fouad Janat
-
Publication number: 20040197870Abstract: The present invention relates to a novel member of the tumor necrosis factor family of receptors. In particular, isolated nucleic acid molecules are provided encoding the human TR9 receptor. TR9 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR9 receptor activity.Type: ApplicationFiled: April 30, 2004Publication date: October 7, 2004Applicant: Human Genome Sciences, Inc.Inventors: Jian Ni, Guo-Liang Yu, Ping Fan, Reiner L. Gentz
-
Publication number: 20040185505Abstract: The invention relates to cytostatin II growth modulatory polypeptides, polynucleotides encoding the polypeptides, methods for producing the polypeptides, in particular by expressing the polynucleotides, and agonists and antagonists of the polypeptides. The invention further relates to methods for utilizing such polynucleotides, polypeptides, agonists and antagonists for applications, which relate, in part, to research, diagnostic and clinical arts.Type: ApplicationFiled: April 13, 2004Publication date: September 23, 2004Applicant: Human Genome Sciences, Inc.Inventors: Jian Ni, Guo-Liang Yu, Reiner L. Gentz
-
Publication number: 20040175801Abstract: The present invention relates to a novel Neutrokine-&agr; protein which is a member of the TNF protein family. In particular, isolated nucleic acid molecules are provided encoding the human Neutrokine-&agr; protein including soluble forms of the extracellular domain. Neutrokine-&agr; polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of Neutrokine-&agr; activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.Type: ApplicationFiled: December 16, 2003Publication date: September 9, 2004Applicant: Human Genome Sciences, Inc.Inventors: Guo-Liang Yu, Reinhard Ebner, Jian Ni
-
Publication number: 20040175802Abstract: The present invention relates to a novel Neutrokine-a, and a splice variant thereof designated Neutrokine-aSV, polynucleotides and polypeptides which are members of the TNF family. In particular, isolated nucleic acid molecules are provided encoding the human Neutrokine-a and/or Neutrokine-aSV polypeptides, including soluble forms of the extracellular domain. Neutrokine-a and/or Neutrokine-aSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of Neutrokine-a and/or Neutrokine-aSV activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.Type: ApplicationFiled: December 19, 2003Publication date: September 9, 2004Applicant: Human Genome Sciences, Inc.Inventors: Guo-Liang Yu, Reinhard Ebner, Jian Ni
-
Publication number: 20040172673Abstract: Disclosed is substantially pure DNA encoding an Arabidopsis thaliana Rps2 polypeptide; substantially pure Rps2 polypeptide; and methods of using such DNA to express the Rps2 polypeptide in plant cells and whole plants to provide, in transgenic plants, disease resistance to pathogens. Also disclosed are conserved regions characteristic of the RPS family and primers and probes for the identification and isolation of additional RPS disease-resistance genes.Type: ApplicationFiled: July 2, 2003Publication date: September 2, 2004Inventors: Frederick M. Ausubel, Brian J. Staskawicz, Andrew F. Bent, Douglas Dahlbeck, Fumiaki Katagiri, Barbara N. Kunkel, Michael Nicholas Mindrinos, Guo-Liang Yu, Barbara Baker, Jeffrey Ellis, John Salmeron
-
Publication number: 20040157258Abstract: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.Type: ApplicationFiled: March 15, 2004Publication date: August 12, 2004Applicant: Human Genome Sciences, Inc.Inventors: Roxanne Duan, Steven M. Ruben, Kimberly A. Florence, John M. Greene, Craig A. Rosen, Paul Young, Ann M. Ferrie, Guo-Liang Yu, Fouad Janat, Jian Ni, Kenneth C. Carter, Gregory A. Endress, Ping Feng, David W. Lafleur, Yanggu Shi
-
Publication number: 20040146893Abstract: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.Type: ApplicationFiled: October 15, 2003Publication date: July 29, 2004Applicant: Human Genome Sciences, Inc.Inventors: Steven M. Ruben, Craig A. Rosen, Paul E. Young, John M. Greene, Jian Ni, Ping Feng, Kimberly A. Florence, Jing-Shan Hu, Ann M. Ferrie, Guo-Liang Yu, Roxanne D. Duan, Fouad Janat
-
Publication number: 20040148643Abstract: The invention provides methods for fusing a first cell with a second cell to form a hybrid cell. The methods involve incubating a first parental cell producing a first partner of a fusogenic binding partner pair on its surface with a second parental cell producing a second partner of the fusogenic binding partner pair on its surface. In certain embodiments, the parental cells are incubated with a known fusogen such as polyethylene glycol and the fusogenic binding partner pair increases the rate of cell fusion. In many embodiments, the first cell is an antibody producing cell, the second cell is an immortal cell, and the hybrid cell is a hybridoma cell that produces a monoclonal antibody. Also provided by the invention are methods for producing hybridoma cells, and methods for screening those cells for production of a monoclonal antibody of interest. The invention further provides systems and kits for carrying out the subject methods.Type: ApplicationFiled: January 23, 2003Publication date: July 29, 2004Inventor: Guo-Liang Yu
-
Publication number: 20040141952Abstract: The present invention relates to novel Death Domain Containing Receptor-5 (DR5) proteins which are members of the tumor necrosis factor (TNF) receptor family, and have now been shown to bind TRAIL. In particular, isolated nucleic acid molecules are provided encoding the human DR5 proteins. DR5 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying antagonists and antagonists of DR5 activity.Type: ApplicationFiled: February 10, 2004Publication date: July 22, 2004Applicant: Human Genome Sciences, Inc.Inventors: Jian Ni, Reiner L. Gentz, Guo-Liang Yu, Craig A. Rosen
-
Publication number: 20040136951Abstract: The present invention relates to novel Death Domain Containing Receptor-5 (DR5) proteins which are members of the tumor necrosis factor (TNF) receptor family, and have now been shown to bind TRAIL. In particular, isolated nucleic acid molecules are provided encoding the human DR5 proteins. DR5 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying antagonists and antagonists of DR5 activity. The invention also relates to the treatment of diseases associated with reduced or increased levels of apoptosis using antibodies specific for DR5, which maybe agonists and/or antagonists of DR5 activity.Type: ApplicationFiled: August 27, 2003Publication date: July 15, 2004Applicant: Human Genome Sciences, Inc.Inventors: Jian Ni, Reiner L. Gentz, Guo-Liang Yu, Craig A. Rosen
-
Publication number: 20040132976Abstract: Human colon specific gene polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polynucleotides or polypeptides as a diagnostic marker for colon cancer and as an agent to determine if colon cancer has metastasized. Also disclosed are antibodies specific to the colon specific gene polypeptides which may be used to target cancer cells and be used as part of a colon cancer vaccine. Methods of screening for agonists and antagonists for the polypeptide and therapeutic uses of the antagonists are disclosed.Type: ApplicationFiled: February 12, 2004Publication date: July 8, 2004Applicant: Human Genome Sciences, Inc.Inventors: Guo-Liang Yu, Craig A. Rosen
-
Patent number: 6759513Abstract: The present invention relates to novel Death Domain Containing Receptor (DR3 and DR3-V1) proteins which are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR3 and DR3-V1 proteins. DR3 and DR3-V1 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of DR3 and DR3-V1 activity.Type: GrantFiled: June 16, 1999Date of Patent: July 6, 2004Assignee: Human Genome Sciences, Inc.Inventors: Guo-Liang Yu, Jian Ni, Reiner L. Gentz, Patrick J. Dillon